Protocol Ledger

NCT04695080 · Phase II/III · ACTIVE NOT RECRUITING

ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Interventional Phase II/III clinical trial protocol NCT04695080 sponsored by Queen Mary University of London in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-25 Enrollment: 204 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04695080
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)204 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04695080
Protocol FieldVerified Registry Value
NCT IdentifierNCT04695080
Consolidated Lead SponsorQueen Mary University of London
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment204 participants (ACTUAL)
Registered Start Date2021-06-25
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI